Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MYOC | Q99972 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11782643 | 0.89 | LMNA (0.49) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R | |
| SCHEMBL11778961 | 0.86 | LMNA (0.51) | KCNH2ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL11780000 | 0.85 | MC4R (0.53) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R | |
| Clefamide SCHEMBL672628 | 0.85 | LMNA (0.46) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R | |
| SCHEMBL11780196 | 0.85 | MC4R (0.53) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R | |
| Teclozan SCHEMBL635666 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11779835 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2LMNAMC4RMEN1 | |
| SCHEMBL11780202 | 0.80 | ALDH1A1 (0.43) | KCNH2ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL11780584 | 0.79 | LMNA (0.46) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R | |
| SCHEMBL11780552 | 0.79 | LMNA (0.45) | KCNH2ALDH1A1SMN1; SMN2LMNAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050142069-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer | NOVADEL PHARMA, INC. | 2005-06-30 | — | — | US | claimed |
| EP-1545458-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | Novadel Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004019912-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030082107-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer | NOVADEL PHARMA INC. | 2003-05-01 | — | — | US | claimed |
| WO-2026090318-A2 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY-Tech Labs, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY TECH LABS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4092139-B1 | METHOD FOR DISCRIMINATING BETWEEN LIVE AND DEAD MICROBES IN A SAMPLE | PATHOQUEST (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | LIPA, LIPC, ACACA | KCNH2 2603/4885ALDH1A1 1598/4885SMN1; SMN2 2432/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | KCNH2 1884/4885ALDH1A1 840/4885SMN1; SMN2 3002/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | KCNH2 4230/4885ALDH1A1 4459/4885SMN1; SMN2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.